This content is intended for Health Care Professionals in the United States.

Vericel develops, manufactures and markets advanced therapies for the sports medicine and severe burn care markets.

Sports Medicine

MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adult patients. MACI is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using health cartilage tissue from the patient's own knee.

MACI Arthro is the first and only FDA-approved autologous cell-based cartilage therapy for arthroscopic delivery. MACI can now be delivered arthroscopically in patients with ≤4 cm2 accessible defects.

For more information, please visit MACI.com.

Severe Burn Care

NexoBrid® (anacaulase-bcdb), a botanical drug product containing proteolytic enzymes, is indicated for the removal of eschar in adult and pediatric patients with deep partial-thickness and/or full-thickness burns.

For more information, please visit NexoBrid-US.com.

Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area.

For more information, please visit Epicel.com.